Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5069 in Knee Osteoarthritis Pain
NCT03956550Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2019
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of Nadecnemab in osteoarthritis (OA) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at 12 weeks. Started May 2019; status: terminated.
02
Drugs
Nadecnemab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03956550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03956550.